We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/4/2018 19:01 | kb.. oh sh*te , sorry about that, took it straight off the twitter feed without checking the date. Too much sun on the noggin this afternoon. Apologies to one and all. 3780p stateside at the moment | philanderer | |
19/4/2018 18:49 | Allergan have ruled out making a bid. Updated - Allergan now released a note saying that they will not submit a bid. | romeike | |
19/4/2018 18:41 | It has according to the Guardian 20 mins ago.... "Allergan, a global company listed in New York and headquartered in Dublin, said it was in the early stages of considering a possible offer for Shire. It added: “No offer has been made. There can be no certainty an offer will be made nor as to the terms on which any such offer would be made. A further announcement will be made as appropriate.” Under takeover rules, Allergan has until 5pm on 17 May to either make a firm offer or walk away. It is the latest twist in the battle to take control of Shire after Takeda said at the end of March that it was considering making an offer. Updating the market on Thursday, the Japanese firm revealed Shire’s board had rejected its offer, which was equivalent to £46.50 a share. Shire's shares surge as Japan's Takeda considers bid Read more Shire responded with its own statement saying that the board had considered three separate offers from Takeda, unanimously rejecting them all on the grounds that they “significantly undervalue the company and Shire’s growth prospects and pipeline”. However, Shire suggested it would be willing to consider an improved offer: “At the board’s request Shire’s advisers entered into a dialogue with Takeda’s advisers to discuss whether a further, more attractive, proposal may be forthcoming and to understand the basis on which such a proposal would be made. “The board and management of Shire remain committed to enhancing shareholder value and are focused on fully evaluating internal and external opportunities to maximise value for shareholders, including any further " | suffersnofools | |
19/4/2018 18:32 | Allergan haven't actually made a statement rulimg out making a bid. | romeike | |
19/4/2018 18:21 | Tiny Tim - Go grab the biggest Turkey you can find! It's a soap opera ;) | suffersnofools | |
19/4/2018 18:17 | 2014 was a long time ago.We should stick with today's comments.Dublin, Ireland - 19 April 2018As previously reported, Allergan plc ("Allergan") is in the process of evaluating a full range of potential strategic actions that will create value for shareholders, such as divestitures, combinations and acquisitions. The company has hired multiple financial advisors to assist in the review of these options.Following recent press speculation, Allergan confirms that it is in the early stages of considering a possible offer for Shire plc ("Shire"). No offer has been made. There can be no certainty an offer will be made nor as to the terms on which any such offer would be made. A further announcement will be made as appropriate. | steeplejack | |
19/4/2018 18:04 | Looks like a good chance to dump this before it heads back down to £30. Takeda have made their bids and they have rightly been rejected. It's not a cash bid it's mostly stock which means it's a merger rather than a take over! Nothing further will come if this in the short term these are simply opportunistic bids and they don't have the cash to fund a cash take over. | blueclyde | |
19/4/2018 17:45 | Nothing will happen now. Shares back to 3800p stateside A lot of burned fingers. | philanderer | |
19/4/2018 17:39 | Blimey that was short lived. Shire directors must be wanting big price. The speed of them pulling out makes me worried Takeda got no chance as well. | billytkid2 | |
19/4/2018 17:39 | post removed, that article was 4 years out of date. Apologies one and all. | philanderer | |
19/4/2018 17:30 | Just announced on CNBC Allergan will NOT bid, oh. | montyhedge | |
19/4/2018 17:28 | It is all here hxxp://www.hl.co.uk/ | romeike | |
19/4/2018 17:20 | Thanks Romeike. What are Allergan cash reserves and current debt? | karateboy | |
19/4/2018 17:19 | Financial advisers for Shire have continued “a dialogue” with Takeda to determine if a more attractive offer will be made. Shire did not comment on the potential offer from Allergan. | philanderer | |
19/4/2018 17:05 | About $58bn based on their share price at ~ $155 but that is not really a true reflection of their scale and capacity to make a bid, as their share price is down from $250 - $300 due to the unpopular action they have tried to take against malicious/frivolous patent challenges and threats to its IP and other factors impacting all of pharma. The reality is they have the resources to make a serious offer that I believe would succeed where Takeda will struggle without being prepared to stretch its balance sheet a lot more and come up with an offer that isn't practically all paper. I hold Allergan myself (though a fraction of my Shire holding) - with my AGN hat on I'd be happy for Allergan to pick up Shire at anything below £58 because at that price they are getting it below fair value and would add considerable long term benefit to AGN with some significant synergies between the two companies. | romeike | |
19/4/2018 17:01 | What is the market cap of Allergan ? If Takeda increases its offer to £50 half cash half shares , big SHP investors may go with that. I think that is what Allergen may do until another more bigger player comes in. | karateboy | |
19/4/2018 17:00 | Yes, agree romeike. Might get a deal sorted by christmas at this rate ;-) | philanderer | |
19/4/2018 16:57 | Takeda offer overloaded with paper and currency risk. Places no value on the Baxalta assets despite the much hyped squeeze on Shire haemophilia revenues failing to materialise thus far. | romeike | |
19/4/2018 16:35 | Above 4300 tomorrow me thinks | ny boy | |
19/4/2018 16:16 | I think takeda are out of their depth here - 46.50 is too low an offer especially considering baxalta and it's potential growth prospects | mbmiah | |
19/4/2018 16:10 | Takeda are up against the clock with a potential rival....they'll have time for one final crack...... sub £50 with less paper??? | soundbuy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions